GlassScriptPhysician profile
Mary A Brown
NPI 1346280492
$4,768.20
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $1,322 · 2021: $1,921.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $591.64 | 2019-2021 | |
| Amgen INC. | $576.52 | 2019-2021 | |
| Glaxosmithkline, LLC. | $531.91 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $456.84 | 2019-2021 | |
| Novo Nordisk INC | $362.80 | 2019-2021 | |
| Abbvie INC. | $281.04 | 2020-2021 | |
| Mylan Specialty L.P. | $274.73 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $208.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.73 | 2019-2020 | |
| Allergan, INC. | $165.46 | 2020 | |
| Merck Sharp & Dohme LLC | $146.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $136.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $133.14 | 2019-2021 | |
| Amarin Pharma, INC. | $121.02 | 2019-2020 | |
| Lilly USA, LLC | $120.89 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $105.33 | 2019 | |
| Nestle Healthcare Nutrition INC. | $70.70 | 2021 | |
| Eisai INC. | $60.13 | 2021 | |
| Daiichi Sankyo INC. | $55.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.91 | 2021 | |
| Therapeuticsmd, INC. | $36.23 | 2019 | |
| Sanofi Pasteur INC. | $23.67 | 2019 | |
| Almatica Pharma LLC | $21.58 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.36 | 2020 | |
| Vifor Pharma, INC. | $21.16 | 2019 | |
| Advanced Respiratory, INC | $17.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.